UNSPSC 51113001: Altretamine

This classification denotes an ethylenimine compound with the molecular formula C9H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8BIH59O7H, chemically known as 2,4,6-tris(dimethylamino)-s-triazine but more generally known as altretamine, which bears US NIH Compound Identifier 2123. European Medicines Agency schedules Altretamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05382MIG.

UNSPSC 51113001 Altretamine, a Commodity code, designates a single pharmaceutical product — altretamine, an alkylating agent used in cancer treatment — but the recent state and local procurement activity recorded under this code reflects broader pharmacy benefit management and direct pharmaceutical purchasing strategy rather than altretamine procurement itself. The Texas Health and Human Services Commission (HHS) issued Request for Information (RFI) No. HHS0017013 on March 27, 2026, seeking vendor capabilities to support a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program, with response due April 3, 2026. The RFI solicits detailed information about vendors' experience with direct contracting for self-insured employers and health plans in both private and government sectors, their capacity to negotiate contracts based on negotiated net pricing models without rebates, and their ability to implement value-based or outcomes-based agreements. This indicates that state health and human services agencies are exploring ways to bypass traditional pharmacy benefit managers, group purchasing organizations, and wholesalers to establish direct relationships with pharmaceutical manufacturers, a structural shift in how states procure prescription medications at scale.

The activity under this code appears limited to exploratory procurement in Texas at the state level. The RFI does not specify set-aside designations, incumbent contractor information, or funding allocations, functioning as a preliminary market intelligence tool to inform the state's future formal RFP strategy rather than a binding competitive solicitation. No award value or budget range is identified in the current materials. The mismatch between the code's nominal scope — a single drug product — and the actual work being solicited — enterprise pharmacy contracting capability and market analysis — suggests that either the code was applied as a placeholder pending more detailed procurement strategy or the opportunity database has tagged a broader pharmaceutical program initiative under a narrow drug-specific code. Absent additional opportunities in the recent record, this code shows minimal direct procurement activity.